Kaempferol sensitizes human ovarian cancer cells-OVCAR-3 and SKOV-3 to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis via JNK/ERK-CHOP pathway and up-regulation of death receptors 4 and 5

Medical Science Monitor

Volumn 23, Issue , 2017, Pages 5096-5105

  Zhao, Yingmei ^a   Tian, Binqiang ^b   Wang, Yong ^a   Ding, Haiying ^a  

^a FUDAN UNIVERSITY PUDONG MEDICAL CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; MAP kinase kinase kinase 3; Ovarian neoplasms; Transcription factor chop

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CELL SURFACE PROTEIN; DEATH RECEPTOR 4; FLICE INHIBITORY PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; KAEMPFEROL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; DEATH RECEPTOR; KAEMPFEROL DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL SURVIVAL; CELL VIABILITY ASSAY; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MRNA EXPRESSION ASSAY; OVARY CANCER; OVCAR-3 CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SKOV3.IP1 CELL LINE; WESTERN BLOTTING; CELL MEMBRANE; CELL PROLIFERATION; DRUG EFFECT; FEMALE; METABOLISM; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KAEMPFEROLS; OVARIAN NEOPLASMS; RECEPTORS, DEATH DOMAIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR CHOP; UP-REGULATION;

EID: 85032455969     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.903552     Document Type: Article

References (45)

1. Ferlay J, Shin H, Bray F et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010; 127: 2893–917
2. Buys SS, Partridge E, Black A et al: Effect of screening on ovarian cancer mortality: The Prostate, Lung Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA, 2011; 305: 2295–303
3. Deraco M, Rossi CR, Pennacchioli E et al: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study. Tumori, 2001; 87: 120–26
4. Agarwal R, Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003; 3: 502–16
5. Zhang C, Zhang Z, Zhang S et al: Targeting of Wnt/β-catenin by anthelmin-tic drug pyrvinium enhances sensitivity of ovarian cancer cells to chemotherapy. Med Sci Monit, 2017; 23: 266–75
6. Ashkenazi A, Pai RC, Fong S et al: Safety and antitumor activity of recom-binant soluble Apo2 ligand. J Clin Investigation, 1999; 104: 155–62
7. Pan G, O’Rourke K, Chinnaiyan AM et al: The receptor for the cytotoxic ligand TRAIL. Science, 1997; 276: 111–13
8. Pan G, Ni J, Wei YF et al: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 1997; 277: 815–18
9. Marsters SA, Sheridan JP, Pitti RM et al: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol, 1997; 7: 1003–6
10. Emery JG, McDonnell P, Burke MB et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 1998; 273: 14363–67
11. Medema JP, Scaffidi C, Kischkel FC et al: FLICE is activated by association with the CD95 death inducing signaling complex (DISC). EMBO J, 1997; 16: 2794–804
12. Kischkel FC, Hellbardt S, Behrmann I et al: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J, 1995; 14: 5579–88
13. Kischkel FC, Lawrence DA, Chuntharapai A et al: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity, 2000; 12: 611–20
14. Mellier G, Huang S, Shenoy K, Pervaiz S: TRAILing death in cancer. Mol Aspects Med, 2010; 31: 93–112
15. Inoue T, Shiraki K, Fuke H et al: Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs, 2006; 17: 261–68
16. Zhang L, Zhu H, Teraishi F et al: Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia, 2005; 7: 594–602
17. Jung YH, Heo J, Lee YJ et al: Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci, 2010; 86: 351–57
18. Han MA, Woo SM, Min KJ et al: 6-Shogaol enhances renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated cytochrome c release and down-regulation of c-FLIP(L) expression. Chem Biol Interact, 2015; 228: 69–78
19. Henrich CJ, Brooks AD, Erickson KL et al: Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation. Cell Death Dis, 2015; 6: e1666
20. Harborne JB, Williams CA: Advances in flavonoid research since 1992. Phytochemistry, 2000; 55: 481–504
21. Ross JA, Kasum CM: Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr, 2002; 22: e19–e34
22. Casagrande F, Darbon JM: Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: Regulation of cyclin-depen-dent kinases CDK2 and CDK1. Biochem Pharmacol, 2001; 61: 1205–15
23. Prasad S, Ravindran J, Sung B et al: Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther, 2010; 9: 856–68
24. Wei G, Zhang GM, Liu Y et al: IFN-γ withdrawal after immunotherapy potentiates B16 melanoma invasion and metastasis by intensifying tumor integrin αvβ3 signaling. Int J Cancer, 2008; 123: 702–8
25. Frese S, Frese-Schaper M, Andres AC et al: Cardiac glycosides initiate Apo2L/ TRAIL induced apoptosis in non-small cell lung cancer cells by upregulation of death receptors 4 and 5. Cancer Res, 2006; 66: 5867–74
26. Yang XC, Tu CX, Luo PH et al: Antimetastatic activity of MONCPT in preclinical melanoma mice model. Invest New Drugs, 2010; 28: 800–11
27. Yadav VR, Sung B, Prasad S et al: Celastrol suppresses invasion of colon and pancreatic cancer cells through the down-regulation of expression of CXCR4 chemokine receptor. J Mol Med, 2010; 88: 1243–53
28. Sung B, Ravindran J, Prasad S et al: Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem, 2010; 285: 35418–27
29. Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol, 2003; 3: 745–56
30. Yamaguchi H, Wang HG: CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem, 2004; 279: 45495–502
31. Lee TJ, Um HJ, Mindo S et al: Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med, 2009; 46: 1639–49
32. LeBlanc HN, Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ, 2003; 10: 66–75
33. Wagner KW, Punnoose EA, Januario T et al: Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med, 2007; 13: 1070–77
34. Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther, 2005; 12: 228–37
35. Ravi R, Bedi GC, Engstrom LW et al: Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappa-B. Nat Cell Biol, 2001; 3: 409–16
36. Deveraux QL, Takahashi R, Salvesen GS, Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 1997; 388: 300–4
37. Secchiero P, Gonelli A, Carnevale E et al: TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation, 2003; 107: 2250–56
38. Horak P, Pils D, Kaider A et al: Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: Overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res, 2005; 11: 8585–91
39. Lee DH, Kim DW, Jung CH et al: Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells. Toxicol Appl Pharmacol, 2014; 279: 253–65
40. Fulda S, Meyer E, Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 2002; 21: 2283–94
41. Tang SY, Zhong MZ, Yuan GJ et al: Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells. Oncol Rep, 2013; 29: 474–80
42. Kruyt FA: TRAIL and cancer therapy. Cancer Lett, 2008; 263: 14–25
43. Fisher MJ, Virmani AK, Wu L et al: Nucleotide substitution in the ectodo-main of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res, 2001; 7: 1688–97
44. Wang H, Gao W: DJ-1 Expression in cervical carcinoma and its effects on cell viability and apoptosis. Med Sci Monit, 2016; 22: 2943–49
45. Jiang M, Lin X, He R et al: Decoy Receptor 3 (DcR3) as a biomarker of tumor deterioration in female reproductive cancers: A Meta-Analysis. Med Sci Monit, 2016; 22: 1850–57